What does the Five Year Forward View mean for pharma?
December 6, 2016 | Five Year Forward View, STPs
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.
Introduction to the 5YFV
When it was launched in October 2014, the Five Year Forward View (5YFV) was hailed as one of the most radical changes in the management and organisation of NHS England since its inception in 1948. Designed by NHS England and five partner organisations, it aims to put an end to the age-old divide between GPs with patients, and consultants with hospitals, and develop new, integrated and cost efficient models of care that suit local needs. In doing so, it aspires to create a sustainable NHS that continues to be funded by the taxpayer, is free at the point of use and able to meet the evolving needs of patients, now and in the future.
How can pharma capitalise on the 5YFV?
The 5YFV is dramatically changing the way that NHS services are run, particularly at a local level. One of the biggest changes here is the planned introduction of STPs – Sustainability and Transformation Plans – in 2017, which will help to deliver 5YFV by providing blueprints for delivering services locally. Instead of taking a one-size fits all approach to healthcare provision, STPs will see the commissioner/provider split replaced by local planning and management within 44 areas across England called ‘footprints’. These area-specific, whole-system plans will identify the health needs of their populations and define how they should be addressed quickly and effectively at a local level. Understanding the bigger picture in terms of how STPs will affect areas such as NHS structure, leadership, commissioning, KPIs, efficiency, procurement and patient pathways is crucial for pharma. The industry also needs to get to grips with the priorities and primary objectives of the individual 44 STPs. Armed with this knowledge, the industry should look to offer tailored solutions that fit in with the aspirations of individual STPs and will help them to fulfil the needs of their local patient populations.
Sharing best practice – how can pharma help?
Sharing best practice is key to accelerating the pace of change within the NHS and since October 2011, NHiS, which is part of Wilmington Healthcare, has been helping to do this through its Mental Health Commissioning Network conferences. The events, which are being sponsored this year by Lundbeck Ltd, Shire Ltd and Sunovion, bring like-minded people together to discuss and exchange ideas on how to treat people with mental health problems in a more integrated way. Wherever possible, they involve locally identified Chairs plus the Strategic Clinical Networks, Academic Health Science Networks and Public Health England. They provide an ideal opportunity for pharma companies to get involved in shaping patient pathways and improving NHS services in line with the objectives of 5YFV.
Conclusion
Since its inception in 2014, 5YFV has been dramatically changing the way that NHS services are run, particularly at local level, and further major changes will occur when STPs are introduced next year. In the midst of this upheaval, there are golden opportunities for pharma to get involved in redesigning NHS services. The key is to keep abreast of the changes, understand the bigger picture and find ways to utilise its expertise to add value.
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond
2019: A pivotal year for the NHS
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the key changes in the NHS in 2019
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan
Millennial Physicians And Digital Health Services
Can Millennial Physicians and Digital Health Services Fix the Patient-Doctor Relationship?
Wilmington Healthcare appoints new consultants
Healthcare intelligence provider Wilmington Healthcare, which incorporates HSJ, Interactive Medica and OnMedica, has expanded its team with the appointment of two new senior consultants - Roger Tomlins and Sarah Shield.
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published
Wilmington Healthcare makes new senior appointment
Healthcare intelligence provider Wilmington Healthcare, which incorporates HSJ, Interactive Medica and OnMedica, has appointed Jonathan Carney as Director of its Insight and Key Account Management (KAM) services.